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Abstract
Objectives To investigate whether there is an association between use
of angiotensin receptor blockers and risk of cancer.
Design Cohort study of risk of cancer in people treated with angiotensin
receptor blockers compared with angiotensin converting enzyme (ACE)
inhibitors. Effects were explored with time updated covariates in Cox
models adjusted for age, sex, body mass index (BMI), diabetes and
metformin/insulin use, hypertension, heart failure, statin use,
socioeconomic status, alcohol, smoking, and calendar year. Absolute
changes in risk were predicted from a Poisson model incorporating the
strongest determinants of risk from the main analysis.
Setting UK primary care practices contributing to the General Practice
Research Database.
Participants 377 649 new users of angiotensin receptor blockers or
ACE inhibitors with at least one year of initial treatment.
Main outcome measures Adjusted hazard ratios for all cancer and
major site specific cancers (breast, lung, colon, prostate) by exposure
to angiotensin receptor blockers and by cumulative duration of use.
Results Follow-up ended a median of 4.6 years after the start of
treatment; 20 203 cancers were observed. There was no evidence of
any increase in overall risk of cancer among those ever exposed to
angiotensin receptor blockers (adjusted hazard ratio 1.03, 95%
confidence interval 0.99 to 1.06, P=0.10). For specific cancers, there
was some evidence of an increased risk of breast and prostate cancer
(1.11, 1.01 to 1.21, P=0.02; and 1.10, 1.00 to 1.20, P=0.04; respectively),
which in absolute terms corresponded to an estimated 0.5 and 1.1 extra
cases, respectively, per 1000 person years of follow-up among those
with the highest baseline risk. Longer duration of treatment did not seem
to be associated with higher risk (P>0.15 in each case). There was a
decreased risk of lung cancer (0.84, 0.75 to 0.94), but no effect on colon
cancer (1.02, 0.91 to 1.16).
Conclusions Use of angiotensin receptor blockers was not associated
with an increased risk of cancer overall. Observed increased risks for
breast and prostate cancer were small in absolute terms, and the lack
of association with duration of treatment meant that non-causal
explanations could not be excluded.
Introduction
Angiotensin II type 1 receptor antagonists (hereafter referred
to as angiotensin receptor blockers) were first approved in 1995
and are widely used to treat heart failure, hypertension, and
diabetic nephropathy. Experimental studies suggest that
angiotensin II receptors play a role in regulating angiogenesis,
cell proliferation, and tumour progression, providing justification
for a theoretical concern about the risk of cancer.1 Clinical
concerns first arose in 2003 from the CHARM (candesartan in
heart failure assessment of reduction in mortality andmorbidity)
trial, which aimed to assess the role of angiotensin receptor
blockers in heart failure.2 There were significantly more fatal
cancers among people randomised to candesartan than placebo
(86 (2.3%) v 59 (1.6%), P=0.038). There was, however, no
difference in the incidence of non-fatal cancers, and the
investigators suggested the findings for fatal cancer could be
attributable to chance. Subsequent trials have produced negative
or inconclusive findings but have lacked power. A systematic
review and meta-analysis of data from randomised trials found
an increased risk of cancer (but not death from cancer)
associated with use of angiotensin receptor blockers,3 but a more
recent meta-analysis incorporating a larger number of trials and
using individual patient data found no increase in either overall
risk or risk of site specific cancer in users of angiotensin receptor
blockers compared with controls.4 Data from observational
studies have similarly found no increase in risk of cancer
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associated with use of angiotensin receptor blockers,5 6 though
such studies had limited follow-up and lacked data on potentially
important confounders such as smoking.
We used the large amount of real world follow-up data available
in the UKGeneral Practice Research Database (www.gprd.com/
products/database.asp) to assess the overall risk of cancer and
the risk of major site specific cancers (lung, breast, prostate,
colon) associated with use of angiotensin receptor blockers
compared with use of a similar class of drug, angiotensin
converting enzyme (ACE) inhibitors, which does not seem to
be associated with cancer risk.7 8 Our hypothesis was that those
exposed to angiotensin receptor blockers had the same risk of
cancer as those exposed only to ACE inhibitors.
Methods
General Practice Research Database
The General Practice Research Database is a clinical database
containing records from computer systems used by general
practitioners to record all clinical information. The database
comprises anonymised computerised medical records from
general practitioners in the United Kingdomwho use the Vision
IT system and that have agreed at the practice level to
participate; about 8% of the UK population are currently
included. The UK has a publicly funded healthcare system
financed through general taxation and free at the point of use
to UK residents; general practitioners play a key role as they
are responsible for primary healthcare and specialist referrals.
Patients are affiliated to a practice, which centralises the medical
information from the general practitioners, specialist referrals,
and admission to hospital. Demographic information, clinically
relevant lifestyle data, prescription details, clinical events,
preventive care provided, specialist referrals, and hospital
admissions and their major outcomes are all recorded in the
database. Data collection started in 1987. Around five million
patients are currently registered, with about 12 million patient
records. A recent systematic review that collected together
studies attempting to validate diagnoses on the database found
that among such studies a median of 95% of neoplasms
identified through records in the database could be confirmed
with alternate data sources.9
Study participants
We retrieved data on all patients aged ≥18 with a first recorded
prescription of an ACE inhibitor or angiotensin receptor blocker
in the years 1995-2010 inclusive and dated at least six months
after the patient’s registration date within General Practice
Research Database. Exposure to ACE inhibitors offered an ideal
comparison because the two drug classes have similar
indications, reducing problems of confounding by indication,
and ACE inhibitors themselves do not seem to be associated
with risk of cancer.7 8 We chose the six month period to ensure
that most of those included would be new users and to exclude
prevalent users with unknown previous duration of treatment.10
ACE inhibitors were defined as all drugs classified in the British
National Formulary, chapter 2.5.5.1, and angiotensin receptor
blockers as all drugs classified under chapter 2.5.5.2.11 Patients
were excluded if they had a recorded diagnosis of cancer on or
before their index date (defined as the date of their first
prescription of an ACE inhibitor or angiotensin receptor
blocker). To prevent pre-existing cancers from affecting our
results—for example, through reverse causality—we excluded
the initial 12 months of person time after the first prescription
for an angiotensin receptor blocker or ACE inhibitor, and
individuals who developed cancer or ended follow-up during
this period did not contribute to our analyses. We also excluded
patients with any treatment breaks of more than 90 days during
this initial qualifying period. Individuals switching from an
ACE inhibitor to an angiotensin receptor blocker during
follow-up left the risk set for 12 months, but could re-enter after
12 months of treatment with an angiotensin receptor blocker;
this additional 12 month exclusion period after a switch was
intended to prevent the estimation of a spurious association if
switching were itself linked to underlying risk of cancer.
Drug exposure and outcomes data
Exposure status was based on prescriptions data in the database.
All prescriptions for an angiotensin receptor blocker or ACE
inhibitor were retrieved and the length of each prescription was
calculated on the basis of the recorded number of tablets
prescribed and the daily dose; when these data were not available
we assumed the median value (28 days). Clinical events are
coded in the database with National Health Service (NHS) Read
codes.12 The Read codes dictionary was first searched to identify
codes indicatingmalignant neoplasms (excluding non-melanoma
skin cancers), by using the Read code hierarchical structure, a
search for keywords, and code lists used in earlier studies. We
then manually reviewed and confirmed codes identified by the
initial search. Subsets of codes specifically indicating neoplasms
of the breast, lung, prostate, and colon were also identified
during this process. In all cases, we excluded codes for
borderline and suspected malignancies. Two researchers (KB
and LS) developed and checked the final code lists. Finally, we
identified cancers among individuals in the study by matching
patients’ database records against these final code lists, with no
reference to exposure status.
Statistical methods
Follow-up time began at the end of the 12 month qualifying
period after the first prescription of either an ACE inhibitor or
angiotensin receptor blocker and ended at the earliest of an
incident diagnosis of cancer or death with cancer listed as a
cause, death from causes other than cancer, transfer out of the
database practice network, or last data collection date for the
practice. For the analyses of specific cancers (lung, breast,
prostate, colon), follow-up was censored at the first occurrence
of any other type of cancer. We examined associations between
risk of cancer and use of an angiotensin receptor blocker in two
ways. For the primary analysis, we used ever exposed to
angiotensin receptor blockers versus never exposed to
angiotensin receptor blocker (that is, treatment with an ACE
inhibitor only) as the main exposure variable, and, after
calculating crude incidence ratios, we included the variable in
adjusted Cox regressionmodels for each outcome. The variable
ever exposed to angiotensin receptor blocker was treated as time
updated so that, for example, people starting treatment with an
ACE inhibitor and switching to an angiotensin receptor blocker
would contribute initial person time as never exposed to an
angiotensin receptor blocker, but person time after the switch
as ever exposed to an angiotensin receptor blocker (fig 1⇓).
Once exposed to angiotensin receptor blockers, however,
patients remained in the ever exposed group even if they
subsequently stopped treatment; we used this strategy because
any causal effect of angiotensin receptor blocker use on cancer
risk would likely manifest as a diagnosis only some time after
harmful exposure. In a secondary analysis, we re-ran our
adjusted Cox models using a time updated variable capturing
cumulative duration of angiotensin receptor blocker exposure
(classified as 12-24, 25-36, 37-48, 48-60, >60 months) in place
of the variable ever exposed to an angiotensin receptor blocker.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e2697 doi: 10.1136/bmj.e2697 (Published 24 April 2012) Page 2 of 16
RESEARCH
Cumulative duration of angiotensin receptor blocker exposure
did not increase during treatment interruptions or
discontinuations of treatments (fig 1⇓). In all cases, our Cox
models were adjusted for the following potential confounders,
evaluated at the index date: age group (18-54, 55-64, 65-74,
≥75, based on approximate quartiles), sex, body mass index
(BMI; underweight, normal, overweight/obese), smoking status
(non-smoker, current smoker, ex-smoker), alcohol status
(non-drinker, ex-drinker, or current drinker—further classified
as light, moderate, heavy, unknown), diabetes status (categorised
as no evidence of diabetes, diabetes without metformin or insulin
use, diabetes with metformin but no insulin use, and diabetes
with any insulin use), hypertension (based on a recording of
diagnosed hypertension or blood pressure >140/90 mm Hg),
heart failure, statin use, index of multiple deprivation score (a
measure of socioeconomic status),13 and calendar year. All of
these variables were included because they could plausibly be
associated with both treatment and cancer risk. First order
interactions between these variables were tested in a preliminary
modelling stage, with a cut off of P<0.001 to reflect the number
of tests involved (55); this led to the identification of several
interactions that were significantly associated with the outcome
(between age and sex, BMI and smoking, smoking and index
of multiple deprivation score, and heart failure and calendar
year). Inclusion of these interactions, however, had little effect
on the hazard ratio associated with the exposure of interest—that
is, there was no suggestion that omission would lead to
confounding—therefore the interactions were not included in
subsequent modelling, in the interests of parsimony and ease
of interpretation of the final model. For the analyses of risk of
breast and prostate cancer, the study population was restricted
to women and men, respectively, and sex was omitted from the
confounder model. The primary analysis excluded the 10% of
individuals with missing data on smoking, alcohol, or BMI;
these patients were included in later sensitivity analyses with
missing category and multiple imputation methods to deal with
the missing covariates.
To estimate the effect of angiotensin receptor blocker exposure
on absolute cancer rates, we included in a Poisson model
variables for which our previous Coxmodel suggested evidence
of an association with cancer. The Poisson model was used to
predict event rates by exposure to angiotensin receptor blocker
in the most recent calendar period (2005 onwards) among those
at highest and lowest baseline risk (men aged ≥75 who were
current smokers and had a history of heart failure, and women
aged 18-54 who had never smoked and had no history of heart
failure, respectively). Finally, in an exploratory analyses we
examined the role of specific angiotensin receptor blockers
(losartan, candesartan, irbesartan, valsartan, telmisartan, other).
For this analysis, patients were assumed to be exposed to only
a single type of angiotensin receptor blocker during follow-up,
taken as the first one prescribed.
Pos hoc analyses, sensitivity analyses, and
model checking
For cancer outcomes that seemed to be associated with use of
angiotensin receptor blockers, we assessed (post hoc)
associations with use in the initial 12 months of exposure to
provide further information onwhether the observed associations
were likely to represent a causal relation: associations in the
first 12 months would argue against this as a causal effect would
be unlikely to operate on such a short timescale.
Several planned sensitivity analyses were then carried out.
Firstly, we extended our initial 12 month exclusion period after
the first prescription for an angiotensin receptor blocker or ACE
inhibitor to two and then three years. Secondly, in case of any
effect of ACE inhibitor use on cancer risk, we used those
prescribed thiazides and related diuretics (as defined by chapter
2.2.1 of the British National Formulary11) as an alternative
comparator group. Thirdly, we repeated the analysis including
the 10% of patients with missing data on smoking, alcohol
status, or BMI. We used two methods for handling the missing
data: firstly, we introduced a separate missing data category for
each of the incomplete variables, and secondly, we usedmultiple
imputation by chained equations, with the imputation model
including all covariates from the main outcome model.14
Fourthly, we repeated the primary analysis using attained age,
rather than time since start of treatment, as the principal time
scale, to provide the finest possible control for age. Fifthly, we
checked the proportional hazards assumption by testing for a
zero slope in the scaled Schoenfeld residuals over time15 and,
as necessary, introduced interactions with analysis time for any
covariates with evidence of non-proportional hazards. Finally,
we carried out a post hoc sensitivity analysis, restricting the
study population to patients without diabetes because of an
imbalance in prevalence of diabetes between treatment groups.
Results
Study population, use of antihypertensive
drugs, and baseline characteristics
Out of 902 322 individuals identified with at least one
prescription of an angiotensin receptor blocker or ACE inhibitor,
377 649 were included in the study with total follow-up of 1.5
million person years (fig 2⇓). Themain exclusions were because
of failure to satisfy the new user criteria (that is, less than six
months’ follow-up in the database before first prescription,
n=279 650), history of cancer (n=38 834), and diagnosis of
cancer or end of follow-up during the initial 12 month lag period
after start of treatment (n=206 006). The median interval from
first ever prescription for an ACE inhibitor or angiotensin
receptor blocker to the end of follow-up was 4.6 years, with
follow-up ending at least five years after the first prescription
for 168 773 individuals (45%). A total of 20 203 cancers were
recorded during follow-up, with the most common specific
cancer being prostate (n=3025), followed by breast (2411), lung
(n=2144), and colon (1516).
Of the 377 649 individuals in the study, 340 589 (90%) started
taking an ACE inhibitor, and 37 060 (10%) started taking an
angiotensin receptor blocker. Of the users of ACE inhibitors,
however, 71 354 (19% of study population) later switched to
an angiotensin receptor blocker; there was little switching in
the other direction (n=3650, table 1⇓). Of the 1 542 323 person
years, patients spent a total of 346 823 (22%) taking an
angiotensin receptor blocker and 1 070 054 (69%) taking an
ACE inhibitor (table 2⇓). The remaining person time was
accounted for by interruptions of treatment (125 446 person
years, 8%). The most widely used specific angiotensin receptor
blockers were losartan, candesartan, irbesartan, and valsartan
(accounting for 31%, 25%, 19%, and 14% of person time,
respectively), while the most common ACE inhibitors were
ramipril, lisinopril and perindopril (43%, 29%, and 16% of
person time, respectively).
Those starting and continuing to take ACE inhibitors were more
likely to be men (55% v ≤48% in other groups), while diabetes
was more common among those starting treatment with ACE
inhibitors, regardless of later switching (baseline prevalence of
diabetes 25%, compared with 17% among those starting
treatment with an angiotensin receptor blocker, hence we
restricted our post hoc sensitivity analysis to those without
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diabetes). Statin use was also higher among those starting
treatment with an ACE inhibitor, but this seemed to be explained
by the higher prevalence of diabetes: when we stratified statin
use by diabetes status, use was similar across the groups (ranging
from 30% to 40% among those without diabetes and 57% to
61% among those with diabetes). Other baseline characteristics
were similar across treatment groups (table 1⇓). There were
somemissing data on smoking status (1%), alcohol status (6%),
and BMI (5%), but 345 832/377 649 individuals (92%) had
complete data on all variables considered in the analysis.
Effect of ever using an angiotensin receptor
blocker
The overall incidence of cancer was similar among those ever
exposed to angiotensin receptor blockers compared with those
never exposed. After adjustment for potential confounders, there
was no evidence that a small observed increase in risk associated
with exposure to an angiotensin receptor blocker represented
any more than chance variation (adjusted hazard ratio for ever
v never exposed 1.03, 95% confidence interval 0.99 to 1.06,
P=0.10; table 3⇓). There was some evidence for an association
between use of angiotensin receptor blockers and cancers of the
breast and prostate (adjusted hazard ratio 1.11, 1.01 to 1.21; and
1.10, 1.00 to 1.20; respectively) but not of the colon (1.02, 0.91
to 1.16). We observed a protective association for lung cancer
(0.84, 0.75 to 0.94).
For those with the highest baseline risk, the estimated absolute
increases in incidence of cancer for those ever exposed to
angiotensin receptor blockers compared with those never
exposed were 0.5 and 1.1 extra cases per 1000 person years for
breast and prostate cancer, respectively. For those with the
lowest baseline risk, our results suggested an extra 0.2 and 0.1
breast and prostate cancers, respectively, per 1000 person years
(table 4⇓).
Role of cumulative duration of angiotensin
receptor blocker use
Figure 3 shows the effect of cumulative duration of use of
angiotensin receptor blockers⇓. There was little evidence that
the risk for any cancer or specific cancers increased with longer
duration of treatment (P>0.15 for trend for any, breast, colon,
and prostate cancer). For lung cancer, there was evidence of a
decreasing trend (P<0.001 for overall trend and P=0.14 for trend
after separate adjustment for ever angiotensin receptor blocker
use—that is, ignoring the zero use category).
Effects of treatment with angiotensin receptor
blocker in first year of treatment
For cancer outcomes that seemed to be associated with
angiotensin receptor blocker use, we carried out a post hoc
analysis to identify any early changes in risk of cancer (in the
12month period that was excluded from our main analysis) that
might suggest non-causal explanations for our findings. For
lung cancer, we observed a suggestion of a raised risk of lung
cancer in the 12 months after start of treatment with an
angiotensin receptor blocker (hazard ratio 1.11, 0.99 to 1.27),
followed by a protective association with longer duration of
treatment. For breast cancer, there was weak evidence of an
increased risk associated with angiotensin receptor blockers in
the first 12 months of use (1.12, 1.01 to 1.24), while for prostate
cancer the point estimate was in the direction of a raised risk in
the first year but the confidence interval suggested that this
could have reflected chance variation (1.07, 0.96 to 1.19).
Role of individual drugs
To investigate differences between individual angiotensin
receptor blockers, we carried out an analysis stratified by the
first specific drug prescribed. For 87% of patients, this
represented the only angiotensin receptor blocker to which they
were exposed during follow-up. There was a suggestion of a
difference between individual drugs in their association with
prostate cancer (P=0.08); the estimated hazard ratios were higher
with candesartan and valsartan than with other drugs (table 5⇓).
For breast cancer and other cancer types there was no evidence
of a difference between individual drugs (P≥0.3 for interaction
in each case).
Sensitivity analyses
After we extended the one year period of person time excluded
after the start of treatment or switching to two and then three
years, effect estimates changed little and in all cases confidence
intervals included our original effect estimates. The estimated
hazard ratios for any cancer were 1.04 (1.00 to 1.08) and 1.03
(0.99 to 1.07) in the two and three year exclusion analyses,
respectively. When we used those prescribed thiazides and
related diuretics instead of ACE inhibitors as the comparator
group, the hazard ratio for any cancer associated with
angiotensin receptor blocker use (with adjustment for ACE
inhibitor use) was 1.00 (0.95 to 1.05), consistent with no effect
on cancer risk. The protective association with lung cancer
remained (0.77, 0.65 to 0.92), while for breast and prostate
cancer the size of the hazard ratios were consistent with the
original analysis, though confidence intervals were wider,
suggesting reduced power, with risk increases no longer
significant (1.11, 0.97 to 1.27; and 1.10, 0.97 to 1.24;
respectively). Our results were robust to the inclusion of the
10% of individuals with missing data; estimates were similar
to our original results, both for any cancer and specific cancers
(adjusted hazard ratio associated with ever using an angiotensin
receptor blocker for any cancer was 1.03 (0.99 to 1.06) with the
missing category analysis and 1.02 (0.99 to 1.06) with the
multiple imputation analysis, compared with 1.03 (0.99 to 1.06)
in the original analysis). Use of age as the primary timescale
rather than time since start of treatment and restriction of the
analysis to those without diabetes led to similar effect estimates
for the exposure of interest (hazard ratios within 0.01 of our
original estimates for any, breast, lung, and prostate cancer and
within 0.04 for colon cancer).
There was no evidence of non-proportional hazards for the
variable of ever using an angiotensin receptor blocker (P=0.72),
but the hazard ratios associated with age group seemed to change
over time (P<0.001). Inclusion of an interaction between age
group and analysis time had little effect on the estimated
association between ever using an angiotensin receptor blocker
and cancer overall (revised hazard ratio 1.03, 1.00 to 1.07).
Estimated hazard ratios for the associations with specific cancers
were also in each case within 0.01 of our original estimates.
Discussion
Main findings
In a large cohort of new users of ACE inhibitors or angiotensin
receptor blockers, we found little evidence of an increase in the
overall risk of a diagnosis of cancer associated with ever using
an angiotensin receptor blocker, and we were able to rule out
any more than a 6% relative increase in risk (estimated hazard
ratio 1.03, 95% confidence interval 0.99 to 1.06, P=0.10). There
was a suggestion that angiotensin receptor blocker use was
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associated with breast cancer in women and prostate cancer in
men, but in absolute terms the estimated increases in risk were
small: among those with the highest baseline risk, our results
suggested one extra case of prostate cancer per 1000 man years
exposed and 0.5 extra cases of breast cancer per 1000 woman
years exposed. As longer duration of treatment did not seem to
be associated with higher risk (P>0.15 in each case), we cannot
exclude non-causal explanations for these observed associations.
There was no increase in risk for cancers of the lung or colon;
indeedwe observed an apparently protective association between
use of angiotensin receptor blockers and lung cancer.
Comparison with other studies
Table 6 presents a summary of key studies to date⇓. Clinical
concerns surrounding potential cancer risks associated with use
of angiotensin receptor blockers arose initially from randomised
trial data. The CHARM trial showed weak evidence of an
increased risk of deaths from cancer among those randomised
to candesartan compared with placebo.2 Several meta-analyses
have followed up this finding. Coleman et al reported a raised
point estimate for the odds ratio for cancer associated with
angiotensin receptor blocker treatment, but confidence intervals
were wide and included 1.8 Sipahi et al found a significantly
increased risk of new cancer among those taking angiotensin
receptor blockers compared with control treatments, and there
was an indication of a raised risk of prostate cancer, though this
did not reach formal significance (P=0.08); in contrast with our
results, the authors also observed a significantly increased risk
of lung cancer.3 Two more recent meta-analyses by the ARB
Trialists Collaboration and Bangalore et al failed to confirm
these findings,4 7 reporting no association between angiotensin
receptor blocker use and cancer: the ARB Trialists analysis
included a wide range of trials and incorporated individual
patient data and unpublished tabulated data on cancer outcomes.
A few included trials reported a significantly protective effect
on lung cancer, and this seemed to cancel out the detrimental
effect in the subset of trials included in the earlier Sipahi et al
meta-analysis: overall, the authors found no evidence for an
altered risk of lung cancer with angiotensin receptor blockers
nor any evidence for an excess risk of prostate, breast, or overall
cancer. Confidence intervals, however, were somewhat wider
than in our study, and it should be noted that positive
associations of the size we have estimated for breast and prostate
cancer would not be ruled out by the confidence intervals
presented in the ARB Trialists analysis, or indeed by the earlier
meta-analyses mentioned above.
This issue highlights one of the limitations of trial data in this
context: even the most comprehensive meta-analysis included
substantially fewer patients than was possible in our study, and
follow-up time ranged from 23 months to a maximum of five
years, while 45% of patients in our study had at least five years
of follow-up available. In addition, randomised trials in this
topic are not designed to detect cancer outcomes, study
populations might inadequately represent the wider population
of patients treated with angiotensin receptor blockers and similar
drug classes, and, even if sufficient follow-up were available,
the benefits of randomisation would probably be lost over the
long term because of switching, non-adherence, and drop out.
Only a few observational studies to date have investigated the
potential cancer risks associated with treatment with angiotensin
receptor blockers. A recent study in Denmark reported no
increase in overall risk of cancer in the preplanned analysis of
angiotensin receptor blocker users compared with ACE inhibitor
users,6 in agreement with our study. The authors also observed
a significantly increased risk of prostate cancer in a post hoc
subgroup analysis, a finding that seems to be supported by our
study, in which prostate cancer was one of four prespecified
site specific outcomes. No increased risk of breast cancer was
observed, but confidence intervals were once again consistent
with the effect size we have observed. For lung cancer, the
estimated relative risk was similar to that in our study, but the
confidence interval included the null (0.92, 0.82 to 1.02).
Finally, a study based on Taiwanese health insurance data
reported more contrasting results, with a substantially and
significantly reduced risk of cancer observed among those
treated with angiotensin receptor blockers,5 but this could be
explained by broader differences between treated and untreated
patients with hypertension, as a large proportion of the control
group in this study did not seem to be receiving antihypertensive
drugs at all.
Possible mechanisms and explanation of
findings
Experimental evidence could support a role for angiotensin II
receptors in the development of cancer. The renin angiotensin
system seems to be involved in angiogenesis, but the exact
mechanisms involved, and indeed the direction of associations,
are not clear. Administration of the angiotensin receptor blocker
losartan in animal models has been linked to both increases16
and decreases17 in angiogenesis. Angiotensin II binds to both
type 1 and type 2 receptors (AT1R and AT2R), and one study
suggests that stimulation of the latter in particular could be key
in mediating in vivo angiogenesis.16 It is therefore possible that
angiotensin receptor blockers could increase the risk of cancer
through removal of the “competition” from AT1R and thus
enabling unopposed AT2R stimulation. Other studies, however,
implicate AT1R stimulation in angiogenesis through triggering
the expression of vascular endothelial and other growth factors18
and genes involved in cellular proliferation,19 in which case
blockade with angiotensin receptor blockers might be expected
to be associated with reduced cancer risk; the blocking of AT1R
has also been shown to induce apoptosis within tumour cells in
vitro.20 The contradictory nature of these various observations
suggest that complexmechanismsmight be at work, and indeed
their relevance in humans and in clinical practice is difficult to
judge.
The lack of convincing associations between duration and
response suggest that we should consider non-causal
explanations for our findings. Firstly, the increases in cancer
risk that we observed for breast and prostate cancer were not
strongly significant and might still reflect chance variation: it
is worth noting that tests of five outcomes subject to a simple
statistical (Bonferroni) correction for multiple testing would
require P<0.01 for a family-wise significance level of 5%. We
did not formally apply this correction as, for non-independent
outcomes, it would likely be overconservative,21 but results with
corresponding P values >0.01 must be treated with caution.
Breast cancer
In a post hoc analysis we observed an increased risk of breast
cancer associated even with less than 12 months’ exposure to
angiotensin receptor blockers, which argues further against a
causal relation. A possible mechanism might involve the use of
angiotensin receptor blockers in those with cough symptoms.
Individuals with cough might be preferentially switched to, or
started on angiotensin receptor blockers, as treatment with ACE
inhibitors is associated with cough as a side effect. But cough
symptomsmight themselves be linked to an undiagnosed cancer,
or, importantly, to a greater likelihood of referral for chest
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radiography and therefore early detection of preclinical breast
cancers. This could explain the immediately increased risk of
breast cancer with short duration of treatment, though it would
be surprising for such an effect to persist in our primary analysis
that excluded the first 12 months of treatment.
Lung cancer
There was weak evidence for a similar early increase in risk of
lung cancer; only after 12months was the association protective.
This would be consistent with a selective switching to
angiotensin receptor blockers among those (perhaps with cough
symptoms) at risk of an imminent diagnosis of lung cancer, and
a consequently depleted pool of individuals at risk of lung cancer
among those with longer duration of treatment. It should be
noted though that we also observed a protective association
between angiotensin receptor blockers and lung cancer in a
sensitivity analysis in which we used thiazides and related
diuretics as an alternative comparator group. These drugs are
not associated with a cough side effect, suggesting that selective
switching because of cough associated with ACE inhibitors
might not be the full explanation. Another possibility is that
increasing cardiovascular risk could lead some patients to
simultaneously start a new antihypertensive drug and also reduce
their smoking, thus lowering their risk of lung cancer. Whether
or not it is causal, it should be noted that the protective
association with lung cancer that we observed is consistent with
observational data from Denmark6 and some individual clinical
trials,4 and the evidence is strengthened by an apparent
association between increasing duration of treatment and greater
protection; we therefore think the relation between use of
angiotensin receptor blockers and risk of lung cancer is worthy
of further study.
Prostate cancer
There was insufficient evidence to confirm an association
between use of angiotensin receptor blockers and prostate cancer
during the initial 12 month exclusion period, and confounding
because of switching associated with cough is unlikely to be an
issue, suggesting that a causal relation could be plausible, but,
as with breast cancer, we did not observe a convincing effect
of duration of treatment on this outcome.
Public health implications
Even if the association is causal, the absolute increases in the
risk of cancer associated with treatment with an angiotensin
receptor blocker that we have observed would need to be
weighed up against likely benefits of treatment. In the results
of the SCOPE trial among elderly patients with mild to moderate
hypertension, treatment with an angiotensin receptor blocker
(candesartan) was associated with 2.9 fewer cases of non-fatal
stroke per 1000 person years, and non-significant reductions in
all stroke and first major cardiovascular event of 3.1 and 3.3
per 1000 person years, respectively.22 In the CHARM-Overall
study (candesartan versus placebo), about 3800 patients with
chronic heart failure in each armwere followed up for a median
of 37.7 months. Treatment with an angiotensin receptor blocker
was associated with five fewer deaths per 1000 person years.2
These figures compare with a maximum estimated increase in
cancer risk corresponding to one extra diagnosis of prostate
cancer per 1000 man years exposed, and 0.5 extra diagnoses of
breast cancer per 1000 woman years exposed, for those with
the highest risks of cancer at baseline. Nevertheless, it would
be desirable to avoid any increase in the risk of such a serious
adverse event. Given that alternative and equally effective
antihypertensive drugs exist,23 our findings, if confirmed by
further evidence suggesting a causal relation, support the
consideration of other classes of drugs in the treatment decision
process, particularly for patients considered to be at the highest
risk of breast or prostate cancer. Further confirmatory studies
and a thorough consideration of the risk-benefit balance will be
needed before changes to treatment guidelines can be
recommended.
Strengths and limitations
Our study has some limitations. Firstly, patients were not
randomised to their treatments. Recent data suggest that
observational studies generally give robust estimates of adverse
effects,24 but care must be taken: in a non-randomised setting,
treatment decisions might be linked to the particular
circumstances or medical history of the patient. In this case, the
decision to use those treated with ACE inhibitors as the main
comparison group should have reduced confounding by
indication as the two classes of drugs have similar indications.
Nevertheless, the reasons for treatment with one class over the
other might have been linked to patients’ health, particularly
given the association of ACE inhibitors with cough. If
angiotensin receptor blockers were selectively prescribed to
those with underlying health problems associated with cancer,
a spurious positive result might have been detected for some
cancers. As we also included those switching to an angiotensin
receptor blocker during follow-up in our analysis, a non-causal
association might have been induced if the reasons for switching
were linked to the underlying cancer risk; we dealt with this
issue by excluding the 12 months of person time after a switch
to an angiotensin receptor blocker, extending this to two and
then three years in sensitivity analyses. We also conducted a
post hoc analysis of data specifically from the first 12 months
of angiotensin receptor blocker use to provide information
regarding the likely causality of associations detected.
A further limitation is that we had no direct data on adherence
to treatment.We used records of prescriptions to define exposure
and some patients, in one or both treatment groups, might not
have taken their drugs regularly, resulting in effective
misclassification and the potential for bias in either direction.
Our study design, however, required that patients had picked
up prescriptions for a 12 month period before the start of
follow-up, with no more than a 90 day gap between
prescriptions. It seems unlikely that a high proportion of
non-adherers would have continued to pick up prescriptions in
this way for an extended period of time and thus qualified for
inclusion in the study. Finally, although our study to our
knowledge had longer follow-up than any previous large scale
study, given generally long lead times associated with cancer
outcomes, we cannot rule out that an important effect might
operate at longer timescales.
Despite these limitations, to our knowledge, our study is the
largest to date to investigate the concerns surrounding
angiotensin receptor blocker use and risk of cancer. We were
able to include a large number of patients in a real world clinical
setting and with relatively long follow-up: 45% of our study
population had follow-up data for at least five years after the
start of treatment. Patients included in General Practice Research
Database have been shown to be representative of the wider
population25 and are not restricted on age or other factors; the
use of routinely collected primary healthcare data also allowed
us to adjust our analyses for multiple confounders including
important lifestyle risk factors such as smoking, BMI, and
alcohol use. Finally, we carried out several sensitivity analyses
and our findings seemed to be robust to changing elements of
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the study design and analysis and the approach used for dealing
with missing data; to using an alternative comparison drug class
in case ACE inhibitors themselves had an effect on cancer risk;
to restricting the study population to people without diabetes;
and to the inclusion of extra terms in the statistical model to
allow for non-proportional hazards.
Conclusions
In a cohort of individuals treated for hypertension, we found no
evidence of an overall increased risk of cancer among those
exposed to angiotensin receptor blockers and a protective
association for lung cancer specifically. There was some
evidence that the risk of breast and prostate cancers could be
raised, though we cannot rule out non-causal mechanisms. In
absolute terms, observed risk increases were relatively small
and must be weighed against the likely benefits of treatment.
Further research might focus on exploring the apparent
protective association with lung cancer, and clarifying whether
patients at high risk of breast or prostate cancer would benefit
from alternative, equally effective antihypertensive drugs; we
recommend that future studies include a careful assessment of
the likely causality of any association.
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What is already known on this topic
Experimental studies suggest that angiotensin II receptors play a role in regulating angiogenesis, cell proliferation, and tumour progression,
suggesting a theoretical pathway through which drugs affecting the rennin-angiotensin system could modify cancer risk
Data from a clinical trial and subsequent meta-analysis suggested an increased risk of cancer outcomes among people randomised to
angiotensin receptor blockers, but a more recent meta-analysis found no such effect
What this study adds
Exposure to angiotensin receptor blockers was not associated with an increased risk of cancer overall in a UK primary care setting, and
there was a protective association with lung cancer
There was an increased risk of breast and prostate cancer among those exposed to angiotensin receptor blockers: for those with the
highest baseline risk, exposure was associated with one extra case per 2000 woman years and 1000 man years, respectively
Longer duration of treatment did not seem to be associated with increasing risk for any cancer type, suggesting that observed risk
increases might have non-causal explanations
Tables
Table 1| Baseline and demographic characteristics by treatment use during follow-up in people prescribed angiotensin receptor blockers
(ARB) or angiotensin converting enzyme (ACE) inhibitors for hypertension. Figures are numbers (percentage) unless otherwise specified
TotalSwitch from ACE inhibitor to ARBACE inhibitor only
Switch from ARB to ACE
inhibitorARB only
377 649 (100)71 354 (19)269 235 (71)3650 (1)33 410 (9)No of patients
Sex:
196 814 (52)31 278 (44)148 633 (55)1748 (48)15 155 (45)Men
180 835 (48)40 076 (56)120 602 (45)1902 (52)18 255 (55)Women
Age (years):
94 964 (25)16038 (22)69 374 (26)925 (25)8627 (26)18-54
98 939 (26)19 497 (27)69 579 (26)999 (27)8864 (27)55-64
98 616 (26)21 067 (30)67 894 (25)979 (27)8676 (26)65-74
85 130 (23)14 752 (21)62 388 (23)747 (20)7243 (22)≥75
64 (18-103)65 (18-99)64 (18-103)64 (21-95)64 (18-103)Median (range)
Smoking status:
193 368 (51)39 717 (56)132 843 (49)1984 (54)18 824 (56)Non-smoker
66 590 (18)9834 (14)50 774 (19)656 (18)5326 (16)Current smoker
114 997 (30)21 616 (30)83 251 (31)1008 (28)9122 (27)Ex-smoker
2694 (1)187 (0)2367 (1)2 (0)138 (0)Missing
Alcohol status:
67 980 (18)12 876 (18)47 881 (18)754 (21)6469 (19)Non-drinker
85 466 (23)16 902 (24)60 364 (22)783 (21)7417 (22)Current (low)
7115 (2)1260 (2)5153 (2)97 (3)605 (2)Current (moderate)
5261 (1)721 (1)4093 (2)43 (1)404 (1)Current (high)
180 585 (48)34 876 (49)128 360 (48)1731 (47)15 618 (47)Current (unknown)
9157 (2)1529 (2)6815 (3)78 (2)735 (2)Ex-drinker
22 085 (6)3190 (4)16 569 (6)164 (4)2162 (6)Missing
BMI category:
9389 (2)1316 (2)7150 (3)74 (2)849 (3)Underweight
79 972 (21)14 402 (20)57 721 (21)768 (21)7081 (21)Normal
269 353 (71)53 340 (75)189 574 (70)2665 (73)23 774 (71)Overweight/obese
18 935 (5)2296 (3)14 790 (5)143 (4)1706 (5)Missing
Diabetes:
91 892 (24)17 386 (24)68 196 (25)664 (18)5646 (17)Yes
285 757 (76)53 968 (76)201 039 (75)2986 (82)27 764 (83)No
Hypertension:
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Table 1 (continued)
TotalSwitch from ACE inhibitor to ARBACE inhibitor only
Switch from ARB to ACE
inhibitorARB only
360 679 (96)69 197 (97)255 103 (95)3588 (98)32 791 (98)Yes
16 970 (4)2157 (3)14 132 (5)62 (2)619 (2)No
Heart failure:
27 481 (7)4553 (6)21 831 (8)108 (3)989 (3)Yes
350 168 (93)66 801 (94)247 404 (92)3542 (97)32 421 (97)No
Statin use:
164 923 (44)29 773 (42)122 042 (45)1216 (33)11 892 (36)Yes
212 726 (56)41 581 (58)147 193 (55)2434 (67)21 518 (64)No
15.9 (10.9-23.7)15.1 (10.6-22.8)16.1 (11.1-23.9)15.9 (11.4-24.5)15.6 (10.8-22.6)Median (IQR) deprivation score*
2005 (2003-8)2005 (2003-8)2006 (2003-8)2004 (2002-6)2005 (2003-7)Median (IQR) calendar year
IQR=interquartile range.
*Index of multiple deprivation.
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Table 2| Use of specific drugs during follow-up time* during which people were taking angiotensin receptor blocker or angiotensin converting
enzyme (ACE) inhibitor
Person years (% person time†)
Angiotensin receptor blocker
106 115 (31)Losartan
86 904 (25)Candesartan
65 233 (19)Irbesartan
49 748 (14)Valsartan
17 999 (5)Telmisartan
13 731 (4)Olmesartan
7590 (2)Eprosartan
346 823 (100)Total
ACE inhibitor
460 179 (43)Ramipril
310 415 (29)Lisinopril
175 388 (16)Perindopril
90 877 (9)Enalapril
11 641 (1)Captopril
7831 (1)Trandolapril
7056 (1)Fosinopril
6183 (1)Quinapril
777 (<1)Cilazapril
740 (<1)Imidapril
19 (<1)Moexipril
1 070 054 (100)Total
*Further 125 446 person years accounted for by breaks in treatment.
†Person time on combinations of drugs contributes to >1 row.
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Table 3| Rate of any and specific cancers by treatment and crude and adjusted hazard ratios in people with hypertension taking angiotensin
receptor blocker (ARB) or angiotensin converting enzyme (ACE) inhibitor
P value†
HR (95% CI)Rate per 1000 person
years (95% CI)Total person timeTotal cancers Adjusted*Crude
Any cancer
0.101.03 (0.99 to 1.06)0.99 (0.96 to 1.02)13.2 (12.8 to 13.6)385 1015077Ever used ARB
1.00‡1.00‡13.1 (12.9 to 13.3)1 157 22215126ACE inhibitor use only
Lung cancer
0.0030.84 (0.75 to 0.94)0.72 (0.65 to 0.80)1.1 (1.0 to 1.2)385 101422Ever used ARB
1.00‡1.00‡1.5 (1.4 to 1.6)1 157 2221722ACE inhibitor use only
Breast cancer
0.021.11 (1.01 to 1.21)1.11 (1.02 to 1.21)3.5 (3.3 to 3.8)221 072780Ever used ARB
1.00‡1.00‡3.1 (3.0 to 3.3)523 1861631ACE inhibitor use only
Prostate cancer
0.041.10 (1.00 to 1.20)1.14 (1.05 to 1.24)4.3 (4.0 to 4.6)164 029700Ever used ARB
1.00‡1.00‡3.7 (3.5 to 3.8)634 0352325ACE inhibitor use only
Colon cancer
0.701.02 (0.91 to 1.16)0.99 (0.88 to 1.11)1.0 (0.9 to 1.1)385 101384Ever used ARB
1.00‡1.00‡1.0 (0.9 to 1.0)1 157 2221132ACE inhibitor use only
*Adjusted for age, sex, BMI, smoking, alcohol, diabetes (with or without metformin/insulin use), hypertension, heart failure, statin use, index of multiple deprivation
score, calendar year.
†From Cox model with angiotensin receptor blocker/ACE inhibitor status treated as time updated covariate. Estimates from Cox model (for any cancer) suggested
that only male sex (1.42, 1.38 to 1.47, older age (5.55, 5.23 to 5.88, for ≥75 v 18-54), smoking (1.49, 1.43 to 1.55), and history of heart failure (1.14, 1.08 to 1.19)
were significantly associated with increased cancer risk. There was also evidence of variation by calendar year (P<0.001).
‡Reference category.
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Table 4| Estimated effect of ever versus never using angiotensin receptor blocker (ARB) on absolute estimates of cancer incidence.* Figures
are estimated incidence rate (per 1000 person years)
High risk group‡Low risk group†
Difference
(ARB−ACE
inhibitor)Ever used ARB
Used ACE
inhibitors only
Difference
(ARB−ACE
inhibitor)Ever used ARB
Used ACE
inhibitors only
1.642.640.90.13.23.1Any cancer
−2.512.314.70.00.10.1Lung cancer
0.54.84.30.22.22Breast cancer
1.18.37.20.10.80.7Prostate cancer
0.12.82.60.00.20.2Colon cancer
ACE inhibitor=angiotensin converting enzyme inhibitor.
*Incidence rates predicted for calendar period 2005-11 from Poisson model incorporating exposure of interest, along with strongest predictors of cancer risk from
main Cox model (age, sex, smoking status, heart failure, calendar period).
†Age 18-54, never smoker, no previous heart failure, and (for non-sex specific cancers) female.
‡Age ≥75, current smoker, previous heart failure, and (for non-sex specific cancers) male.
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Table 5| Effect of ever versus never* using angiotensin receptor blocker (ARB), stratified by first specific drug used, on risk of specific
cancers
Hazard ratio (95% CI)Specific drug
Any cancer
1.04 (0.98 to 1.09)Losartan
1.04 (0.98 to 1.11)Candesartan
1.02 (0.95 to 1.09)Irbesartan
1.04 (0.96 to 1.12)Valsartan
0.99 (0.87 to 1.14)Telmisartan
0.97 (0.85 to 1.10)Other
Lung cancer
0.84 (0.70 to 1.00)Losartan
0.99 (0.81 to 1.21)Candesartan
0.71 (0.55 to 0.93)Irbesartan
0.90 (0.70 to 1.16)Valsartan
0.78 (0.48 to 1.25)Telmisartan
0.60 (0.36 to 1.02)Other
Breast cancer
1.04 (0.91 to 1.19)Losartan
1.07 (0.90 to 1.26)Candesartan
1.11 (0.92 to 1.33)Irbesartan
1.19 (0.99 to 1.44)Valsartan
1.36 (1.00 to 1.86)Telmisartan
1.34 (0.99 to 1.81)Other
Prostate cancer
0.98 (0.85 to 1.13)Losartan
1.32 (1.13 to 1.54)Candesartan
1.04 (0.86 to 1.27)Irbesartan
1.17 (0.97 to 1.43)Valsartan
1.03 (0.72 to 1.47)Telmisartan
0.96 (0.67 to 1.37)Other
Colon cancer
1.14 (0.96 to 1.37)Losartan
0.89 (0.70 to 1.14)Candesartan
1.08 (0.85 to 1.39)Irbesartan
0.93 (0.70 to 1.24)Valsartan
0.90 (0.54 to 1.51)Telmisartan
0.95 (0.59 to 1.54)Other
*Comparison group was patients who had taken only ACE inhibitor.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e2697 doi: 10.1136/bmj.e2697 (Published 24 April 2012) Page 13 of 16
RESEARCH
Table 6| Summary of key studies to date investigating associations between angiotensin receptor blocker (ARB) use and cancer outcomes
Cancer resultMain comparison
groupDescription
Exposed to
ARB/total Site specificAny
Trial data
—Fatal: 2.3% v 1.6%,
P=0.038; non-fatal:
5.1% v 4.6%, P=0.49
PlaceboCHARM efficacy trial3803/7601Pfeffer, 20032
Meta-analyses of randomised trials
Lung: 1.01 (0.90 to 1.14);
prostate: 1.04 (0.93 to 1.16);
breast: 1.08 (0.92 to 1.27)*
1.00 (0.95 to 1.04)*Placebo (11 trials); ACE
inhibitor (2 trials); others
(2 trials)
Trials of antihypertensive drugs; individual
patient data/tabulated data on cancer
outcomes available
73 808/138 760ARB trialists
collaboration,
20114
—1.01 (0.93 to 1.09)*
v placebo
Mixed control groupsTrials of antihypertensive drugs with
reported data on cancer outcomes, or
where such information could be obtained
from investigators
41 454/324 168Bangalore, 20117
Lung: 1.25, 1.05 to 1.49);
prostate: 1.15 (0.99 to 1.34);
breast: 0.99 (0.74 to 1.32)†
1.08 (1.01 to 1.15)†Placebo (3 trials); ACE
inhibitor (1 trial); other
(1 trial)
Trials of ARB with reported data on cancer
outcomes
35 015/61 590Sipahi, 20103
—1.12 (0.87 to 1.47)*
v placebo
Mixed control groupsTrials of antihypertensive drugs reporting
data on overall cancer incidence
9550/126 137Coleman, 20088
Observational studies
Lung: 0.92 (0.82 to 1.02); male
genital organs: 1.15 (1.02 to
1.28); breast: 1.01 (0.90 to 1.13);
digestive organs: 0.96 (0.88 to
1.04)†
0.99 (0.95 to 1.03)†ACE inhibitor usersDatabase study with Danish registry data,
including those with record of ARB or ACE
inhibitor use
107 466/317 158Pasternak, 20116
Lung: 0.57 (0.49 to 0.66);
genitourinary system: 0.67 (0.59
to 0.76); breast: 0.66 (0.52 to
0.82); digestive system: 0.63
(0.58 to 0.69)‡
0.66 (0.63 to 0.68)‡Exposed v not exposedStudy using Taiwanese health insurance
data, including patient with diagnosis of
hypertension (but not necessarily treated)
40 124/109 002Huang, 20115
Melanoma: 1.1 (0.7 to 1.5)*—Exposed v not exposedCase control study with melanoma cases
andmatched controls, with Dutch drug and
pathology databases
30/1318 cases;
148/6786 controls
Koomen, 200927
Breast: 1.01 (0.67 to 1.51)†—Exposed v not exposedDatabase study with Danish registry data,
including those with record of
antihypertensive drug use
3053/49 950Fryzek, 200628
Renal: 1.1 (0.6 to 2.2)†—Exposed v not exposedDatabase study with Danish registry data,
including those with record of
antihypertensive drug use
13 755/113 298Fryzek, 200529
*Odds ratio.
†Rate ratio.
‡Hazard ratio.
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Figures
Fig 1 Assignation of time varying variable for ever exposed to angiotensin receptor blocker (ARB) and duration of angiotensin
receptor blocker use during follow-up under four example scenarios
Fig 2 Inclusion and exclusion of study participants. ARB=angiotensin receptor blocker
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Fig 3 Effect of cumulative duration (from end of initial one year qualifying treatment period) of angiotensin receptor blocker
(ARB) use on risk of all cancer and specific cancers. Hazard ratios are from Cox models with cumulative duration of use
treated as time updated covariate, adjusted for age, sex (except models for breast/prostate cancers), BMI, smoking, alcohol,
diabetes, metformin use, index of multiple deprivation score, and calendar year. Effect estimate for “ever used” is from
primary analysis model ignoring number of prescriptions and is shown for comparison
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